The healthcare sector is facing an ongoing challenge of hospital bed shortages, which become even more critical during emergencies or widespread health crises. To address this issue, the startup Doccla is pioneering a solution with its “hospital at home” technology, enabling doctors to remotely monitor and manage patients who may not require physical hospitalization.
Recently, Doccla raised £35 million ($46 million) in a Series B funding round, led by Lakestar, with participation from Elaia and other existing investors. This investment marks a significant milestone for Doccla, as it looks to expand its operations beyond the UK and Ireland into other European markets like Germany, Austria, and France.
Doccla’s “hospital at home” services are designed around a suite of monitoring devices and a mobile app that allows patients to submit health data directly to their electronic health records. This data is then monitored by doctors through a clinician dashboard, which sends alerts when any diagnostic readings require attention. This setup not only alleviates the pressure on hospital resources but also provides peace of mind for patients and their families.
While Doccla’s initial growth was driven by the urgent demands of the COVID-19 pandemic, the startup has since adopted a more strategic approach. Co-founder Martin Ratz emphasized the company’s revenue-first mentality, focusing on securing contracts in new markets before expanding into them. This approach has already proven successful in Germany, and Doccla plans to replicate this model in other countries as well.
In addition to serving health services, Doccla is also exploring opportunities in the pharmaceutical industry. The startup is using its technology to support virtual clinical trials, helping pharmaceutical companies conduct faster and more cost-effective drug testing.
Doccla is navigating a competitive landscape that includes companies like Graphnet and Huma. However, its device-agnostic approach and the ability to offer in-app messaging and video consultations set it apart from competitors. By continuing to innovate and expand, Doccla is well-positioned to become a leader in the virtual hospital space.
Faq,s : Doccla Secures $46 Million for Expanding Hospital at Home Services in Europe
What is the focus of Doccla’s recent funding?
Doccla raised $46 million to expand its “hospital at home” services across Europe, including entering new markets like Germany, Austria, and France.
How does Doccla’s technology benefit patients?
Doccla’s “hospital at home” technology allows doctors to monitor patients remotely, reducing hospital strain and providing peace of mind to patients and families.
Who led the latest funding round for Doccla?
The $46 million Series B funding round for Doccla was led by Lakestar, with participation from Elaia and other existing investors.
2 thoughts on “Doccla Raises $46M in Series B Funding Led by Lakestar”